NASDAQ:AVTE Aerovate Therapeutics (AVTE) Stock Price, News & Analysis $19.15 -0.60 (-3.04%) As of 08/3/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsDividendFinancialsInsider TradesOptions ChainSEC FilingsTrendsBuy This Stock About Aerovate Therapeutics Stock (NASDAQ:AVTE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Aerovate Therapeutics alerts:Sign Up Key Stats Today's Range$18.55▼$20.0050-Day Range$14.98▼$22.5352-Week Range$89.95▼$99.05Volume651,162 shsAverage Volume53,591 shsMarket Capitalization$555.06 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Aerovate Therapeutics is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for patients with debilitating pulmonary diseases. By leveraging a proprietary aerosol delivery platform, the company aims to deliver potent small-molecule anti-fibrotic and anti-inflammatory agents directly to the lungs, thereby maximizing local drug exposure while minimizing systemic side effects. The company’s lead product candidate is an inhaled formulation of an established anti-fibrotic agent currently in early-phase clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF). In addition to its IPF program, Aerovate is advancing preclinical molecules designed to target other chronic lung conditions, including scleroderma-related interstitial lung disease and chronic obstructive pulmonary disease. Each program is engineered to exploit the company’s aerosol technology, which is designed to enhance pulmonary deposition and improve patient tolerability compared with oral therapies. Founded in 2020 and headquartered in the United States, Aerovate Therapeutics has assembled a team of experienced drug developers and clinicians to shepherd its pipeline through clinical development. The company collaborates with leading research institutions and regulatory authorities to support trial design and anticipate broader geographic expansion, positioning Aerovate to address significant unmet needs in fibrotic and inflammatory lung diseases worldwide.AI Generated. May Contain Errors. Read More Receive AVTE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aerovate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AVTE Stock News HeadlinesJade Biosciences Completes Closing of Merger with Aerovate Therapeutics and Previously Announced Private Placement of Approximately $300 MillionApril 28, 2025 | globenewswire.comAerovate Stockholders Approve Merger Proposal With Jade BiosciencesApril 23, 2025 | nasdaq.comHe bet half his $9 billion on ONE stockOne of the most successful fund managers of the past 50 years put more than $4.5 billion - over half his fund - into a single, little-known company. His firm then bought more shares for 61 straight trading days, and the former CEO of Google soon struck a nine-figure partnership with the same company. This company controls nearly a million acres of scarce, irreplaceable minerals now protected by a White House executive order signed January 14, 2026. It has already outperformed Apple, Amazon, and the S-P 500 combined - and Whitney Tilson believes the biggest gains are still ahead.August 4 at 1:00 AM | Stansberry Research (Ad)Aerovate Therapeutics stockholders approve proposed merger with Jade BiosciencesApril 23, 2025 | markets.businessinsider.comAerovate Therapeutics Stockholders Approve Proposed Merger with Jade Biosciences and All Related ProposalsApril 21, 2025 | prnewswire.comAerovate Therapeutics declares special cash dividend, estimated $2.40 per shareApril 10, 2025 | markets.businessinsider.comAerovate Therapeutics sees $67.6M-$69.6M dividend in connection with JadeApril 9, 2025 | markets.businessinsider.comAerovate Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Jade BiosciencesApril 9, 2025 | prnewswire.comSee More Headlines AVTE Stock Analysis - Frequently Asked Questions How have AVTE shares performed this year? Aerovate Therapeutics' stock was trading at $15.43 at the start of the year. Since then, AVTE shares have increased by 24.1% and is now trading at $19.15. How were Aerovate Therapeutics' earnings last quarter? Aerovate Therapeutics, Inc. (NASDAQ:AVTE) announced its earnings results on Friday, April, 25th. The company reported ($3.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($10.50) by $7.35. When did Aerovate Therapeutics' stock split? Aerovate Therapeutics's stock reverse split on Tuesday, April 29th 2025.A 1-35 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 28th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Aerovate Therapeutics IPO? Aerovate Therapeutics (AVTE) raised $122 million in an initial public offering (IPO) on Tuesday, June 29th 2021. The company issued 8,682,142 shares at $13.00-$15.00 per share. How do I buy shares of Aerovate Therapeutics? Shares of AVTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aerovate Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aerovate Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Palo Alto Networks (PANW), Tesla (TSLA) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings4/25/2025Today8/04/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:AVTE CIK1798749 Webaerovatetx.com Phone617-443-2400FaxN/AEmployees20Year Founded2018Profitability EPS (Trailing Twelve Months)($1.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$75.52 million Net MarginsN/A Pretax MarginN/A Return on Equity-90.19% Return on Assets-77.47% Debt Debt-to-Equity RatioN/A Current Ratio8.78 Quick Ratio8.78 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.96 per share Price / Book4.84Miscellaneous Outstanding Shares28,985,000Free Float21,685,000Market Cap$555.06 million OptionableOptionable Beta0.95 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:AVTE) was last updated on 8/4/2026 by MarketBeat.com Staff. From Our PartnersHe knows what's coming this yearAn investor famous for predicting the 2008 housing crash has quietly built a $185 million stake in a small Ame...Behind the Markets | SponsoredPass by August 7… or wait until 2027?The Supreme Court just handed down a digital-privacy ruling that most crypto investors haven't connected to th...Crypto 101 Media | SponsoredYour book attachedBill Poulos is giving away his 'Simple Options Trading For Beginners' book at no cost - normally $29.97. It ou...Profits Run | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored1 Stock to Own by July 31stA scheduled announcement on July 31st could reshuffle the stock market's winners and losers - and one lesser-k...Chaikin Analytics | SponsoredNew Dollar Plan Could Drain Your Account (Silently)Washington's so-called 'Mar-a-Lago Accord' aims to deliberately weaken the U.S. dollar to boost exports and br...Priority Gold | SponsoredTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aerovate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aerovate Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AVTE Stock Alerts